# The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

> **NCT05874674** · NA · RECRUITING · sponsor: **Wonju Severance Christian Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Dialysis; Complications
- Bleeding

## Interventions

- **DRUG:** Nafamostat Mesylate

## Key facts

- **NCT ID:** NCT05874674
- **Lead sponsor:** Wonju Severance Christian Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874674, "The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05874674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*